Progenics Pharmaceuticals (PGNX) 10-K 8 Mar 18 2017 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2017	Mar. 05, 2018	Jun. 30, 2017
Document Information [Line Items]
Entity Registrant Name	Progenics Pharmaceuticals Inc
Entity Central Index Key	835,887
Trading Symbol	pgnx
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		72,661,983
Entity Public Float			$ 204,694,687
Document Type	10-K
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	FY
Amendment Flag	false

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
ASSETS
Cash and cash equivalents	$ 90,642	$ 138,909
Accounts receivable, net	3,972	4,864
Other current assets	2,256	4,328
Total current assets	96,870	148,101
Property and equipment, net	4,122	4,760
Intangible assets, net	30,369	30,581
Goodwill	13,074	13,074
Other assets	1,522	2,470
Total assets	145,957	198,986
LIABILITIES AND STOCKHOLDERS' EQUITY
Accounts payable	3,359	567
Accrued expenses	9,555	15,790
Current portion of debt, net	2,445
Total current liabilities	15,359	16,357
Long-term debt, net	47,242	49,453
Contingent consideration liability	16,800	14,200
Deferred tax liability	1,575	13,010
Other liabilities	1,528	1,204
Total liabilities	82,504	94,224
Commitments and Contingencies
Stockholders’ equity:
Preferred stock, $0.001 par value Authorized - 20,000 shares; issued and outstanding - none	0	0
Common stock, $0.0013 par value Authorized - 160,000 shares; issued - 71,645 shares in 2017 and 70,390 shares in 2016	93	92
Additional paid-in capital	609,829	598,069
Treasury stock at cost, 200 shares of common stock	(2,741)	(2,741)
Subscription receivable	(2,109)
Accumulated other comprehensive loss	(33)	(85)
Accumulated deficit	(541,586)	(490,573)
Total stockholders’ equity	63,453	104,762
Total liabilities and stockholders’ equity	$ 145,957	$ 198,986

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares shares in Thousands	Dec. 31, 2017	Dec. 31, 2016
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	20,000	20,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par vaule (in dollars per share)	$ 0.0013	$ 0.0013
Common stock, shares authorized (in shares)	160,000	160,000
Common stock, shares issued (in shares)	71,645	70,390
Treasury stock at cost, shares (in shares)	200	200

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenue:
Royalty income	$ 10,965	$ 10,295	$ 6,608
License revenue	690	59,081	1,955
Other revenue	43	53	113
Total revenue	11,698	69,429	8,676
Operating expenses:
Research and development	42,589	37,569	28,196
General and administrative	24,909	23,356	18,184
Change in contingent consideration liability	2,600	(4,600)	1,600
Total operating expenses	70,098	56,325	47,980
Operating (loss) income	(58,400)	13,104	(39,304)
Other (expense) income:
Interest (expense) income, net	(4,285)	(527)	52
Total other (expense) income	(4,285)	(527)	52
(Loss) income before income tax (expense) benefit	(62,685)	12,577	(39,252)
Income tax benefit (expense)	11,672	(1,844)	133
Net (loss) income	(51,013)	10,733	(39,119)
Net loss attributable to noncontrolling interests		(73)	(7)
Net (loss) income attributable to Progenics	$ (51,013)	$ 10,806	$ (39,112)
Net (loss) income per share attributable to Progenics - basic (in dollars per share)	$ (0.73)	$ 0.15	$ (0.56)
Weighted-average shares - basic (in shares)	70,284	70,003	69,716
Net (loss) income per share attributable to Progenics - diluted (in dollars per share)	$ (0.73)	$ 0.15	$ (0.56)
Weighted-average shares - diluted (in shares)	70,284	70,155	69,716

Consolidated Statements of Comp

Consolidated Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net (loss) income	$ (51,013)	$ 10,733	$ (39,119)
Other comprehensive loss:
Foreign currency translation adjustments	52	(62)	(26)
Comprehensive (loss) income	(50,961)	10,671	(39,145)
Comprehensive loss attributable to noncontrolling interests		(73)	(7)
Comprehensive (loss) income attributable to Progenics	$ (50,961)	$ 10,744	$ (39,138)

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) shares in Thousands, $ in Thousands	Common Stock [Member]	Common Stock Subscribed [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Receivables from Stockholder [Member]	Treasury Stock [Member]	Noncontrolling Interest [Member]	Total
Balance (in shares) at Dec. 31, 2014	69,833						(200)
Balance at Dec. 31, 2014	$ 91		$ 589,826	$ (462,267)			$ (2,741)		$ 124,909
Net (loss) income				(39,112)				$ (7)	(39,119)
Acquisition of Subsidiary								504	504
Purchase of noncontrolling interests								(292)	(292)
Other comprehensive loss					$ (26)				(26)
Stock-based compensation expense			2,948						2,948
Exercise of stock options (in shares)	313
Exercise of stock options			1,737						1,737
Foreign currency translation adjustments									(26)
Balance (in shares) at Dec. 31, 2015	70,146						(200)
Balance at Dec. 31, 2015	$ 91		594,511	(501,379)	(26)		$ (2,741)	205	90,661
Net (loss) income				10,806				(73)	10,733
Purchase of noncontrolling interests			(239)					(129)	(368)
Stock-based compensation expense			2,457						2,457
Exercise of stock options (in shares)	244
Exercise of stock options	$ 1		1,340						1,341
Foreign currency translation adjustments					(59)			(3)	(62)
Balance (in shares) at Dec. 31, 2016	70,390						(200)
Balance at Dec. 31, 2016	$ 92		598,069	(490,573)	(85)		$ (2,741)		104,762
Net (loss) income				(51,013)					(51,013)
Stock-based compensation expense			4,142						$ 4,142
Exercise of stock options (in shares)	80								80
Exercise of stock options			469						$ 469
Foreign currency translation adjustments					52				52
Return of purchase premium for noncontrolling interests			15						15
Issuance of common stock in connection with at-the-market offering, net of commissions and issuance costs (in shares)	855
Issuance of common stock in connection with at-the-market offering, net of commissions and issuance costs	$ 1		5,025						5,026
Subscription of common stock in connection with at-the-market offering, net of commissions (in shares)	320
Subscription of common stock in connection with at-the-market offering, net of commissions			2,109			$ (2,109)
Balance (in shares) at Dec. 31, 2017	71,645						(200)
Balance at Dec. 31, 2017	$ 93		$ 609,829	$ (541,586)	$ (33)	$ (2,109)	$ (2,741)		$ 63,453

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Cash flows from operating activities:
Net (loss) income	$ (51,013)	$ 10,733	$ (39,119)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:
Stock-based compensation expense	4,142	2,457	2,948
Depreciation and amortization	1,121	2,078	565
Gain on sale of fixed assets	10	(296)	(2)
Paid in-kind interest	(13)	765
Non-cash interest expense	247	38
Deferred income tax	(11,435)	1,811	(133)
Change in fair value of contingent consideration liability	2,600	(4,600)	1,600
Changes in assets and liabilities:
Accounts receivable	892	(1,322)	(3,415)
Other current assets	2,046	1,314	(3,058)
Other assets	947	(778)	(1,535)
Accounts payable	2,779	243	(202)
Accrued expenses	(6,274)	6,581	2,354
Deferred tax and other current liabilities		(158)	(60)
Other liabilities	323	343	(80)
Net cash (used in) provided by operating activities	(53,628)	19,209	(40,137)
Cash flows from investing activities:
Acquisition of subsidiary, net of cash acquired			(6,202)
Purchases of property and equipment	(269)	(4,286)	(370)
Proceeds from sale of fixed assets	37	347	48
Net cash used in investing activities	(232)	(3,939)	(6,524)
Cash flows from financing activities:
Net proceeds from issuance of long-term debt		48,650
Net proceeds from issuance of common stock in connection with at-the-market offering	5,026
Proceeds from exercise of stock options	469	1,340	1,737
Return of estimated interest payment for noncontrolling interest	15	(368)	(292)
Net cash provided by financing activities	5,510	49,622	1,445
Effect of currency rate changes on cash and cash equivalents	83	(86)	17
Net (decrease) increase in cash and cash equivalents	(48,267)	64,806	(45,199)
Cash and cash equivalents at beginning of period	138,909	74,103	119,302
Cash and cash equivalents at end of period	90,642	138,909	74,103
Noncash financing activity
Subscription receivable	$ 2,109

Note 1 - Organization and Busin

Note 1 - Organization and Business	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	1. Business Progenics Pharmaceuticals, Inc. and its subsidiaries (“the Company,” “Progenics,” “we” or “us”) develop innovative medicines and other technologies to target and treat cancer. Our pipeline includes: 1 ® 1095, 2 1404 TM 3 W e licensed our first ® July 2016, On October 31, 2017, NDA for AZEDRA. The FDA has accepted our NDA for review, granted our request for Priority Review, and set an action date of April 30, 2018 no no We have in the past considered opportunities for strategic collaborations, out-licenses, and other arrangements with biopharmaceutical companies involving proprietary research, development and clinical programs, and we continue to do so. We may Our current principal sources of revenue from operations are royalty, development and commercial milestones, and sublicense revenue-sharing payments from Valeant and Bayer AG (“Bayer”). Royalty and further milestone payments from Valeant or Bayer depend on success in development and commercialization, which is dependent on many factors, such as Valeant or Bayer’s respective efforts, decisions by the FDA and other regulatory bodies, competition from drugs for the same or similar indications, and the outcome of clinical and other testing of the licensed products. We commenced principal operations in 1988, 1997, , and related business activities. Certain of our intellectual property rights are held by wholly-owned subsidiaries. All of our U.S. operations are presently conducted at our headquarters in New York, and the operations of our wholly-owned foreign subsidiary, EXINI Diagnostics A.B. (“EXINI”), are conducted at our facility in Lund, Sweden. We operate under a single research and development operating segment. Liquidity At December 31, 201 7, $90.6 $48.3 $138.9 December 31, 2016. one 10 may During the fourth 2017, $5.0 Note 10 . Stockholders’ Equity 2016, $48.7 Note 9. may

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Business Description and Accounting Policies [Text Block]	2. Basis of Presentation The consolidated financial statements have been prepared on the basis of accounting principles generally accepted in the U.S. (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including but not Principles of Consolidation The condensed consolidated financial statements include the accounts of Progenics as well as its wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. In December 2015, December 8, 2016, of EXINI and, as of that date, EXINI became a wholly-owned subsidiary with 100% December 2016, $368 $15 2017. Foreign Currency Translation O ur international subsidiaries generally consider their respective local currency to be their functional currency. Assets and liabilities of these international subsidiaries are translated into U.S. dollars at quarter-end exchange rates and revenues and expenses are translated at average exchange rates during the quarter and year-to-date period. Foreign currency translation adjustments for the reported periods are included in accumulated other comprehensive loss (“AOCL”) in our condensed consolidated statements of comprehensive loss, and the cumulative effect is included in the stockholders’ equity section of our condensed consolidated balance sheets. Realized gains and losses denominated in foreign currencies are recorded in operating expenses in our condensed consolidated statements of operations and were not December 31, 2017, 2016, 2015. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may Revenue Recognition We recognize revenue from all sources based on the provisions of the U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104 104” 605 605, Revenue Recognition 605, 605 If we are involved in a steering or other committee as part of a multiple-deliverable arrangement, we assess whether our involvement constitutes a performance obligation or a right to participate. For those committees that are deemed obligations, we will evaluate our participation along with other obligations in the arrangement and will attribute revenue to our participation through the period of our committee responsibilities. We recognize revenue for payments that are contingent upon performance solely by our collaborator immediately upon the achievement of the defined event if we have no 605 Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Amounts not one Royalty revenue is recognized in the period the sales occur, provided the royalty amounts are fixed or determinable, collection of the related receivable is reasonably assured and we have no During the past three D uring 2016, $50.7 $50.0 $0.7 2016, $7.0 $4.0 $3.0 During 2015 , we recognized $1.5 first 2B/3 140. Research and Development Expenses Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries ; payroll taxes; employee benefits; materials; supplies; maintenance of research equipment; costs related to research collaboration and licensing agreements; the purchase of in-process research and development; the cost of services provided by outside contractors, including services related to our clinical trials; and the full cost of manufacturing drug for use in research, pre-clinical development, and clinical trials. All costs associated with research and development are expensed as incurred. At each period end , we evaluate the accrued expense balance related to these activities based upon information received from the suppliers and estimated progress towards completion of the research or development objectives to ensure that the balance is reasonably stated. Such estimates are subject to change as additional information becomes available. Patents As a result of research and development efforts conducted by us, we have applied, or are applying, for a number of patents to protect proprietary inventions. All costs associated with patents are expensed as incurred. Net (Loss) Income Per Share We prepare earnings per share (“EPS”) data in accordance with ASC 260 260, Earnings Per Share 2017 2015, 2016, not Comprehensive (Loss) Income Comprehensive (loss) income represents the change in net assets of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive (loss) income includes net (loss) income adjusted for the changes in foreign currency translation adjustment. The disclosures required by ASC 220 220, Comprehensive Income 2017, 2016, 2015 no Note 10. Concentrations of Credit Risk Financial instruments which potentially subject us to concentrations of risk consist principally of cash, cash equivalents, and receivables. We invest our excess cash in money market funds, which are classified as cash and cash equivalents. We have established guidelines that relate to credit quality, diversification and maturity and that limit exposure to any one no Cash and Cash Equivalents We consider all highly liquid investments which have maturities of three December 31, 2017 2016, $87.2 $137.3 two $3.4 $1.6 two Accounts Receivable We estimate the level of accounts receivable which ultimately will be uncollectable based on a review of specific receivable balances, industry experience and the current economic environment. We reserve for affected accounts receivable an allowance for doubtful accounts. At December 31, 2017, no In-Process Research and Development , Othe r Identified Intangible Assets and Goodwill The fair values of in-process research and development ( “IPR&D”) and other identified intangible assets acquired in business combinations are capitalized. The Company utilizes the “income method”, which applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected sales revenues and estimated costs or “replacement costs”, whichever is greater. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each IPR&D project and other identified intangible assets independently. IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Other identified intangible assets are amortized over the relevant estimated useful life. The IPR&D assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment and any impairment loss is recognized in our consolidated statements of operations. Goodwill represents excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not may fair value of the reporting unit (the Company has determined that it has only one No December 31, 2017 2016. Fair Value Measurements In accordance with ASC 820 820, Fair Value Measurements and Disclosures three 820 three ● Level 1 . ● Level 2 1 not . ● Level 3 To estimate the fair values of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may Recurring Fair Value Measurements We believe the carrying amounts of our cash equivalents, accounts receivable, other current assets, other assets, accounts payable, and accrued expenses approximated their fair values as of December 31, 2017 2016. The fair value of the contingent consideration liability represents future potential milestone payments related to the Molecular Insight acquisition. The fair value of the contingent consideration liability is categorized as a Level 3 4. Nonrecurring Fair Value Measurements Our non-financial assets, such as intangible assets and property and equipment, are measured and recorded at fair value on the acquisition date, and if indicators of impairment exist, we assess recoverability by measuring the amount of any impairment by comparing the carrying value of the asset to its then-current estimated fair value (for intangible assets) or to market prices for similar assets (for property and equipment). If the carrying value is not No December 31, 2017. O ther current assets are comprised of prepaid expenses, interest, other receivables, and, in the 2016 one 2016 1 Fixed Assets Leasehold improvements, furniture and fixtures, and equipment are stated at cost. Furniture, fixtures and equipment are depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized on a straight-line basis over the life of the lease or of the improvement, whichever is shorter. Costs of construction of long-lived assets are capitalized but are not Expenditures for maintenance and repairs which do not Computer equipment (in years) 3 Machinery and equipment (in years) 5 - 7 Furniture and fixtures (in years) 5 Leasehold improvements (in years) Earlier of life of improvement or lease Deferred L ease L iability and Incentive Our lease agreements include fixed escalations of minimum annual lease paymen ts and we recognize rental expense on a straight-line basis over the lease terms and record the difference between rent expense and current rental payments as deferred lease liability. Deferred lease incentive includes a construction allowance from our landlord which is amortized as a reduction to rental expense on a straight-line basis over the lease term. As of December 31, 2017, 2016, 2017 2016 Other current liabilities: Deferred lease incentive $ 26 $ 26 Other liabilities: Deferred lease liability $ 1,225 $ 876 Deferred lease incentive $ 303 $ 328 Income Taxes We account for income taxes in accordance with the provisions of ASC 740 (Topic 740, Income Taxes In accordance with ASC 718 (Topic 718, Compensation – Stock Compensation 505 505, Equity No. 2016 09, Compensation – Stock Compensation (Topic 718 2016 09” January 1, 2017, Uncertain tax positions are accounted for in accordance with ASC 740, to take on a tax return. ASC 740 not 740 may may 50% 740. 50% 740 twelve Note 13. Risks and Uncertainties To date, w e have relied principally on external funding, license agreements with Valeant, Bayer and others, out-licensing and asset sale arrangements, and royalty and product revenue to finance our operations. There can be no third 2017, 2016, 2015, no December 31, 2017 2016 Legal Proceedings From time to time, we may egardless of the merits, is inherently uncertain. The assessment of whether a loss is probable or reasonably possible, and whether the loss or a range of loss is estimable, often involves a series of complex judgments about future events. We record accruals for contingencies to the extent that the occurrence of the contingency is probable and the amount of liability is reasonably estimable. If the reasonable estimate of liability is within a range of amounts and some amount within the range appears to be a better estimate than any other, then we record that amount as an accrual. If no not Impact of Recently Issued and Adopted Accounting Standards Recently Adopted In March 2016, Financial Accounting Standards Board (the “FASB”) issued ASU 2016 09, Compensation – Stock Compensation (Topic 718 January 1, 2017. December 31, 2017, not Not In January 2017, No. 2017 01 2017 01” Business Combinations (Topic 805 2017 01 December 15, 2017, not In January 2017, No. 2017 04 2017 04” Intangibles - Goodwill and Other (Topic 350 2 2 2017 04 December 15, 2019. January 1, 2017. not In November 2016, No. 2016 18 2016 18” Statement of Cash Flows (Topic 230 2016 18 2016 18 December 15, 2017, not In August 2016, No. 2016 15 2016 15” Statement of Cash Flows (Topic 230 eight 8 1 2 zero 3 4 5 6 7 8 2016 15 2016 15 December 15, 2017 not In February 2016, No. 2016 02, Leases (Topic 842 2016 02” . 2016 02 2016 02 December 15, 2018, In January 2016, No. 2016 01, Recognition and Measurement of Financial Assets and Financial Liabilities 2016 01” 2016 01 2016 01 December 15, 2017. not not In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09” 1 2 3 4 5 2014 09 December 15, 2017. 2016, We identified four 1 2 3 4 January 1, 2018 $0.1 not

Note 3 - Goodwill and Acquired

Note 3 - Goodwill and Acquired Intangible Assets	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Intangible Assets Disclosure [Text Block]	3. I ntangible assets and goodwill were initially measured at the acquisition date at estimated fair value and capitalized for the acquisitions of our wholly-owned subsidiaries EXINI and Molecular Insight. The following table summarizes the activity related to goodwill and intangible assets: Other Intangible Goodwill IPR&D Assets Balance at January 1, 2016 $ 13,074 $ 28,700 $ 2,093 Amortization expense - - (212 ) Balance at December 31, 2016 13,074 28,700 1,881 Amortization expense - - (212 ) Balance at December 31, 2017 $ 13,074 $ 28,700 $ 1,669 The following table reflects the components of the finite-lived intangible assets as of December 31, 201 7: Gross Amount Accumulated Amortization Net Carrying Value Finite lived intangible assets $ 2,120 $ 451 $ 1,669 Total $ 2,120 $ 451 $ 1,669 The weighted-average remaining life of the finite-lived intangible assets was approximately eight December 31, 2017. Amortization expense was calculated on a straight-line basis over the estimated useful life of the asset and was $212 December 31, 2017 2016. no $212 five 2018 2022 .

Note 4 - Fair Value Measurement

Note 4 - Fair Value Measurements	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Fair Value Disclosures [Text Block]	4 . Fair Value Measurements We record the contingent consideration liability resulting from our acquisition of Molecular Insight at fair value in accordance with ASC 820 820, Fair Value Measurement The following tables summarize each major class of our financial assets and liabilities measured at fair value on a recurring basis as of the dates indicated, classified by valuation hierarchy (in thousands): Fair Value Measurements at December 31, 2017 Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Balance at Identical Assets Inputs Inputs December 31, 2017 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 87,231 $ 87,231 $ - $ - Total assets $ 87,231 $ 87,231 $ - $ - Liabilities: Contingent consideration liability $ 16,800 $ - $ - $ 16,800 Total liabilities $ 16,800 $ - $ - $ 16,800 Fair Value Measurements at December 31, 2016 Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Balance at Identical Assets Inputs Inputs December 31, 2016 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 137,340 $ 137,340 $ - $ - Total assets $ 137,340 $ 137,340 $ - $ - Liabilities: Contingent consideration liability $ 14,200 $ - $ - $ 14,200 Total liabilities $ 14,200 $ - $ - $ 14,200 The contingent consideration liability of $16.8 14.2 December 31, 2017 2016, Milestone payments due upon first Program Consideration Form of Payment at Progenics' Option AZEDRA $ 8,000 Cash or Progenics common stock 1404 10,000 Cash or Progenics common stock 1095 5,000 Cash or Progenics common stock $ 23,000 Net sales milestone payments due upon first Calendar Year Net Sales Level (in millions) Consideration Form of Payment at Progenics' Option $ 30 $ 5,000 Cash or Progenics common stock $ 60 5,000 Cash or Progenics common stock $ 100 10,000 Cash or Progenics common stock $ 250 20,000 Cash or Progenics common stock $ 500 30,000 Cash or Progenics common stock $ 70,000 We consider this liability a Level 3 one The estimated fair value was determined based on probability adjusted discounted cash flow and Monte Carlo simulation models that included significant estimates and assumptions pertaining to commercialization events and sales targets. The most significant unobservable inputs were the probabilities of achieving regulatory approval of the development projects and subsequent commercial success, and discount rates. Significant changes in any of the probabilities of success would result in a significantly higher or lower fair value measurement, respectively. Significant changes in the probabilities as to the periods in which milestones will be achieved would result in a significantly lower or higher fair value measurement, respectively. We record the contingent consideration liability at fair value with changes in estimated fair values recorded in change in contingent consideration liability in our condensed consolidated statements of operations. The following table s summarizes quantitative information and assumptions pertaining to the fair value measurement of the Level 3 December 31, 2017 2016 2017 $2.6 Fair Value at December 31, Range 2017 Valuation Technique Unobservable Input (Weighted-Average) Contingent Consideration Liability: AZEDRA commercialization $ 5,500 Probability adjusted Probability of success 72% discounted cash flow model Period of expected milestone achievement 2018 Discount rate 10% 1404 commercialization 4,500 Probability adjusted Probability of success 59% discounted cash flow model Period of expected milestone achievement 2020 Discount rate 10% 1095 commercialization 400 Probability adjusted Probability of success 16% discounted cash flow model Period of expected milestone achievement 2025 Discount rate 10% Net sales targets 6,400 Monte-Carlo simulation Probability of success 16% - 72% Discount rate 10% Total $ 16,800 Fair Value at December 31, Range 2016 Valuation Technique Unobservable Input (Weighted-Average) Contingent Consideration Liability: AZEDRA commercialization $ 3,800 Probability adjusted Probability of success 54% discounted cash flow model Period of expected milestone achievement 2018 Discount rate 10% 1404 commercialization 4,700 Probability adjusted Probability of success 59% discounted cash flow model Period of expected milestone achievement 2019 Discount rate 10% 1095 commercialization 400 Probability adjusted Probability of success 16% discounted cash flow model Period of expected milestone achievement 2024 Discount rate 10% Net sales targets 5,300 Monte-Carlo simulation Probability of success 16% - 59% Discount rate 10% Total $ 14,200 For those financial instruments with significant Level 3 Liability - Contingent Consideration Fair Value Measurements Using Significant Unobservable Inputs (Level 3) 2017 2016 Balance at beginning of period $ 14,200 $ 18,800 Fair value change included in net income (loss) 2,600 (4,600 ) Balance at end of period $ 16,800 $ 14,200 Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period $ 2,600 $ (4,600 )

Note 5 - Accounts Receivable

Note 5 - Accounts Receivable	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Loans, Notes, Trade and Other Receivables Disclosure [Text Block]	5 . Accounts Receivable Our a ccounts receivable represent amounts due to us from collaborators, royalties, and sales of research reagents, and consisted of the following at December 31, 2017 2016: 2017 2016 Royalties $ 3,683 $ 2,407 Collaborators 13 2,000 Other 276 457 Accounts receivable, net $ 3,972 $ 4,864

Note 6 - Fixed Assets

Note 6 - Fixed Assets	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	6 . Fixed Assets Fixed assets as of December 31, 201 7 2016 2017 2016 Machinery and equipment $ 2,516 $ 1,493 Leasehold improvements 1,734 1,640 Computer equipment 714 695 Furniture and fixtures 874 877 Construction in progress - 893 Property and equipment, gross 5,838 5,598 Less - accumulated depreciation (1,716 ) (838 ) Property and equipment, net $ 4,122 $ 4,760 At December 31, 201 7 2016, $1.6 12.8 13.8 September 30, 2030. $0.9 $1.9 $0.5 2017, 2016, 2015,

Note 7 - Accrued Expenses

Note 7 - Accrued Expenses	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	7 . Accrued Expenses The carrying value of our accrued expenses approximates fair value as it represents amounts that will be satisfied within one Accrued expenses consisted of the following at December 31, 2017 2016: 2017 2016 Accrued clinical trial costs $ 2,570 $ 4,885 Accrued payroll and related costs 2,400 1,957 Accrued consulting and service fee expenses 1,860 1,026 Accrued legal and professional fees 1,022 1,123 Accrued contract manufacturing costs 666 2,048 Loss contingency for litigation - 4,000 Other 1,037 751 Accrued expenses $ 9,555 $ 15,790

Note 8 - Commitments and Contin

Note 8 - Commitments and Contingencies	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	8 . Commitments and Contingencies Operating Leases At December 31, 201 7, September 2030 ( December 2018. Rental payments are recognized as rent expense on a straight-line basis over the term of the lease. In addition to rents due under these agreements, we are obligated to pay additional facilities charges, including utilities, taxes and operating expenses. As of December 31, 2017, Years ending Minimum Annual December 31, Payments 2018 $ 1,877 2019 1,818 2020 1,852 2021 1,886 2022 2,134 Thereafter 18,549 Total $ 28,116 Rental ex pense totaled approximately $1.9 $1.2 $1.9 2017, 2016, 2015, 2017 2016, $323 $210 2015 $49 2017, 2016, 2015 $0.1 $1.1 $2.5 Licensing , Service , and Supply Agreements We have entered into intellectual property-based license and service agreements in connection with product development programs, and have incurred milestone, license and sublicense fees and supply costs, included in research and development expenses, totaling approximately $343 $324 $388 2017, 2016, 2015, Paid from inception/acquisition to December 31, 2017 Future Commitments (1) Terms Amgen Fremont, Inc. (formerly Abgenix) $ 1,350 $ 5,750 Milestones and royalties to use XenoMouse ® Former member of PSMA LLC $ 428 $ 52,188 Annual minimum royalty payments and milestones to use technology related to PSMA. University of Zurich and the Paul Scherrer Institute $ 500 $ 840 Annual maintenance and license fee payments, milestones and royalties in respect of licensed technology related to 1404. University of Western Ontario $ 78 $ 257 Annual minimum royalty, administration and milestone payments in respect of licensed technology related to AZEDRA. Johns Hopkins University Technology $ 150 $ 2,760 Annual minimum royalty payments and milestones to use technology related to PyL. Selexis Commercial License Agreement $ 59 $ 1,792 Milestones and royalties to use Selexis technology related to PSMA Antibodies. ( 1 Amounts based on known contractual obligations as specified in the respective license agreements, which are dependent on the achievement or occurrence of future milestones or events and exclude amounts for royalties which are dependent on future sales and are unknown. In addition, w e are planning to out-license or terminate non-germane licenses and service agreements, as to which we have paid $4.9 December 31, 2017, $28.5 Consulting Agreements As part of our research and development efforts, we have from time to time entered into consulting agreements with external scientific specialists. These agreements contain various terms and provisions, including fees to be paid by us and royalties, in the event of future sales, and milestone payments, upon achievement of defined events, payable by us. Certain of these scientists are advisors to us, and some have purchased our common stock or received stock options which are subject to vesting provisions. We have recognized expenses with regard to the consulting agreements of $326 $164 $54 2017, 2016, 2015, Legal Proceedings On January 4, 2017, 2010 federal Sarbanes-Oxley law by terminating him. In connection with this settlement, we and the former employee exchanged mutual releases and we paid an aggregate sum of $4.0 On October 7, 2015 (Valeant’s predecessor as licensee of RELISTOR) received notification of a Paragraph IV certification for certain patents for RELISTOR ® On October 28, 2015, d notification of a Paragraph IV certification with respect to the same patents for RELISTOR subcutaneous injection from Actavis LLC as a result of Actavis LLC’s filing of an ANDA with the FDA, also challenging these patents and seeking to obtain approval to market a generic version of RELISTOR subcutaneous injection before some or all of these patents expire. In October 2016 , Progenics, Valeant, and Wyeth LLC received a notification of a Paragraph IV certification with respect to certain patents for RELISTOR Tablets. The certification accompanied the filing by Actavis LLC of an ANDA challenging such patents for RELISTOR Tablets and seeking to obtain approval to market a generic version of RELISTOR tablets before some or all of these patents expire. In accordance with the Drug Price Competition and Patent Term Restoration Act (commonly referred to as the Hatch-Waxman Act), Progenics and Valeant timely commenced litigation against each of these ANDA filers in order to obtain an automatic stay of FDA approval of the ANDA until the earlier of (i) 30 not In addition to the above described ANDA notifications, in October 2015 three e. The oppositions were filed separately by each of Actavis Group PTC ehf. and Fresenius Kabi Deutschland GmbH. Each of the above-described proceedings is in its early stages and Progenics and Valeant continue to cooperate closely to vigorously defend an d enforce RELISTOR intellectual property rights. Pursuant to the RELISTOR license agreement between Progenics and Valeant, Valeant has the first We are or may

Note 9 - Non-recourse Long-term

Note 9 - Non-recourse Long-term Debt, Net	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Debt Disclosure [Text Block]	9. No n -Recourse Long-Term Debt, Net On November 4, 2016, $50.0 no 9.5%. Under the terms of the loan agreement, payments of interest and principal, if any, under the loan will be made on the last day of each calendar quarter out of RELISTOR royalty payments received since the immediately preceding payment date. On each payment date prior to March 31, 2018, March 31, 2018, 50 September 30, 2021, June 30, 2025. January 1, 2018, In connection with the Royalty-Backed Loan, the debt issuance costs have been recorded as a debt discount in our consolidated balance sheets and are being amortized and recorded as interest expense throughout the life of the loan using the effective interest method. As of December 31, 201 7, no Future principal , based upon estimated sales projections, under the Royalty-Backed Loan as of December 31, 2017, 2018 $ 2,686 2019 3,738 2020 4,858 2021 8,156 2022 12,069 Thereafter 19,245 Total payments $ 50,752 Interest expense, including amortization of debt discount, related to the Royalty-Backed Loan for the year ended December 31, 201 7 $5.1

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	10 . Stockholders’ Equity Common Stock and Preferred Stock We are authorized to issue 160 $.0013, 20 $.001. Shelf Registration During the first 2017, $250 .0 3 January 2017 may $75.0 During the fourth 2017, 854,606 $5.0 $6.06 December 31, 2017, 320,182 $2.1 $6.79 $2.1 as a reduction of stockholders’ equity in our consolidated balance sheet at December 31, 2017. Accumulated Other Comprehensive Loss (“AOCL”) The following table summarizes the components of AOCL at December 31, 2017: Foreign Currency Translation AOCL Balance at January 1, 2017 $ (85 ) $ (85 ) Foreign currency translation adjustment 52 52 Balance at December 31, 2017 $ (33 ) $ (33 ) We did not 2017.

Note 11 - Stock-based Compensat

Note 11 - Stock-based Compensation	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11 . S tock -Based Compensation Equity Incentive Plans W e adopted the following stockholder-approved equity incentive plans: ● The 1996 "1996 5,000,000 options, restricted shares, stock appreciation rights, performance shares, and phantom stock. The 1996 2006. 1996 ● The 2005 "2005 11,450,000 2005 March 25, 2024. The stock option plans provide that options may 100% may ten three five Stock Options The following table summarizes stock options activity for the year ended December 31, 201 7: Weighted Weighted Average Number Average Remaining of Shares Exercise Price Contractual Life Outstanding at January 1, 2017 4,887 $ 7.57 5.81 Granted 1,232 $ 10.34 Exercised (80 ) $ 5.89 Cancelled (159 ) $ 8.96 Expired (345 ) $ 22.42 Outstanding at December 31, 2017 5,535 $ 7.25 6.04 Exercisable at December 31, 2017 3,736 $ 6.71 4.77 Vested and expected to vest at December 31, 2017 5,227 $ 7.15 5.87 The weighted average fair value of options granted during 201 7, 2016, 2015 $6.96, $3.24, $5.02 The total intrinsic value (the excess of the market price over the exercise price) was approximately $ 2.7 $2.0 $2.6 December 31, 2017. 2017, 2016, 2015 $233 $476 $465 Stock-Based Compensa tion Expense We account for stock-based awards issued to employees in accordance with the provisions of ASC 718 718, Compensation – Stock Compensation three five 718 505 50 50 505, Equity 718, We estimated the fair value of the stock options granted on the date of grant using a Black-Scholes valuation model that used the weighted average assumptions noted in the following table. The risk-fr ee interest rate assumption we use is based upon U.S. Treasury interest rates appropriate for the expected life of the awards. The expected life (estimated period of time that we expect employees, directors, and consultants to hold their stock options) was estimated based on historical rates for three zero not not The following table presents assumptions used in computing the fair value of option grants during 2017, 2016, 2015: 2017 2016 2015 Risk-free interest rate 2.17% 1.53% 2.00% Expected life (in years) 6.76 6.77 6.97 Expected volatility 72% 74% 81% Expected dividend yield -- -- -- Stock-based compensation expense for the years ended December 31, 2017, 2016, 2015 2017 2016 2015 Research and development expenses $ 1,371 $ 843 $ 1,099 General and administrative expenses 2,771 1,614 1,849 Total stock-based compensation expense $ 4,142 $ 2,457 $ 2,948 At December 31, 201 7, $5.5 2.3

Note 12 - Employee Savings Plan

Note 12 - Employee Savings Plan	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Compensation and Employee Benefit Plans [Text Block]	1 2 . Employee Savings Plan The terms of the amended and restated Progenics Pharmaceuticals 401 “401 401 50% 1% 10% three December 31, 2017, 401 may $302 $281 $327 401 December 31, 2017, 2016, 2015, No

Note 13 - Income Taxes

Note 13 - Income Taxes	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Income Tax Disclosure [Text Block]	1 3 . Income Taxes We account for income taxes using the liability method in accordance with ASC 740 (Topic 740, Income Taxes On December 22, 2017, , commonly referred to as the Tax Cuts and Jobs Act (“Tax Act”). The Tax Act makes broad and complex changes to the U.S. tax code, including, but not 1 35% 21% 2 one 3 4 5 6 7 8 December 31, 2017. In 201 7, $11.7 $6.6 $4.8 $0.2 2017 18.6%. 2016, $1.8 14.7%. 2016 2015, $133 2015 0.3%. We have completed calculations through June 30, 2016, 382, June 30, 2016, may Our accounting for the following elements of the Tax Act is not not we have recorded provisional amounts pursuant to the guidance within SEC Staff Accounting Bulletin No. 118 118” 2017 2018 . Reduction of U.S. federal corporate tax rate : The Tax Act reduces the corporate tax rate to 21%, January 1, 2018. $3.7 2017. Deemed Repatriation Transition Tax : The Deemed Repatriation Transition Tax (“Transition Tax”) is a tax on previously untaxed accumulated and current earnings and profits (“E&P”) of certain of our foreign subsidiaries. To determine the amount of the Transition Tax, we must determine, in addition to other factors, the amount of post- 1986 The components of the (benefit from) provision for income taxes during each of the three December 31, 2017 2017 2016 2015 Current taxes: United States $ 3 $ 11 $ - Foreign - - - State (16 ) 22 - Total current taxes $ (13 ) $ 33 $ - Deferred taxes: United States $ (8,777 ) $ - $ - Foreign - - - State (2,882 ) 1,811 (133 ) Total deferred taxes $ (11,659 ) $ 1,811 $ (133 ) (Benefit from) provision for income taxes $ (11,672 ) $ 1,844 $ (133 ) Deferred tax assets and liabilities as of December 31, 2017 2016 2017 2016 Deferred tax assets: Depreciation and amortization $ 100 $ 788 Research & Experimental and Orphan Drug tax credit carry-forwards 33,496 27,361 NYS investment tax credit carry-forwards 1,284 933 AMT credit carry-forwards - 221 Net operation loss carry-forwards 177,313 227,171 Capitalized research and development expenditures 3,066 11,915 Stock compensation 5,666 12,343 Other items 1,279 4,513 Total gross deferred tax assets 222,204 285,245 Less valuation allowance (217,382 ) (285,245 ) Deferred tax assets 4,822 - Deferred tax liability (6,397 ) (13,010 ) Net deferred tax liability $ (1,575 ) $ (13,010 ) We maintain a tax valuation allowance on substantially all deferred tax assets considering our history of taxable losses and the uncertainty regarding our ability to generate sufficient taxable income in the future to utilize these deferred tax assets. For 2017 2016, December 31, 2017 2016. 2017 2016, $1.6 $13.0 The following is a reconciliation of the U.S. statutory income tax rate to our effective tax rate for the years ended December 31, 2017, 2016, 2015: 2017 2016 2015 U.S. Federal statutory rate 34.0 % 34.0 % 34.0 % State income taxes, net of Federal benefit 1.5 % 10.8 % 4.8 % Foreign rate differential (0.6% ) 2.6 % (0.1% ) Research and experimental and Orphan Drug tax credit 9.4 % (63.0% ) 1.7 % Effect of federal and state tax rate changes (6.1% ) (43.0% ) (4.8% ) Tax reform impact 13.9 % - - Permanent differences (4.4% ) 0.1 % (1.4% ) Stock option shortfalls (3.1% ) 22.3 % (6.1% ) Change in valuation allowance (26.0% ) 50.9 % (27.8% ) Effective tax rate 18.6 % 14.7 % 0.3 % As of December 31, 201 7, $664.8 2018 2037. $569.0 2030 2037. We have reviewed our nexus in various tax jurisdictions and our tax positions related to all open tax years for events that could change the status of our tax liability under ASC 740, not, no 740 10 no As of December 31, 2017, not 1997. No December 31, 2017, 2016, 2015. Our R&E and Orphan Drug tax credit carry-forwards of approximately $34.2 December 31, 2017 2018 2037. As of December 31, 2017, 2016, not not The following is a tabular reconciliation of the total amounts of unrecognized tax benefits for the years ended December 31, 201 7 2016. 2017 2016 Beginning uncertain tax benefits $ 2,661 $ 2,661 Prior year - increases (decreases) (710 ) - Current year - increases (decreases) - - Settlements - - Expired statuses - - Ending uncertain tax benefits $ 1,951 $ 2,661

Note 14 - Net (Loss) Income Per

Note 14 - Net (Loss) Income Per Share	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Earnings Per Share [Text Block]	1 4 . Net (Loss) Income Per Share Our basic net (loss) income per share attributable to Progenics amounts have been computed by dividing net (loss) income attributable to Progenics by the weighted-average number of common shares outstanding during the period. For 2017 2015 not 2017 2015. 2016, In applying the treasury stock method for the calculation of diluted EPS, amounts of unrecognized compensation expense are required to be included in the assumed proceeds in the denominator of the diluted EPS calculation unless they are anti-dilutive. We have made an accounting policy decision to calculate windfall tax benefits/shortfalls, for purposes of diluted EPS calculation, excluding the impact of deferred tax assets. This policy decision will apply when we have net income and windfall tax benefits/shortfalls are realizable. The calculations of net (loss) income per share, basic and diluted, are as follows: Net (loss) income Weighted-average attributable shares to Progenics outstanding Per share (Numerator) (Denominator) amount 2017 Basic and diluted $ (51,013 ) 70,284 $ (0.73 ) 2016 Basic $ 10,806 70,003 $ 0.15 Dilutive effect of stock options - 152 Diluted $ 10,806 70,155 $ 0.15 2015 Basic and diluted $ (39,112 ) 69,716 $ (0.56 ) The following table summarizes anti-dilutive common shares or common shares where performance conditions have not 2017 2016 2015 Stock options 2,395 3,577 6,381 Contingent consideration liability (1) 2,824 1,644 2,827 Total securities excluded 5,219 5,221 9,208 ___________________________ ( 1 Calculated as follows: (a) the contingent consideration liability balance at December 31

Note 15 - Unaudited Quarterly R

Note 15 - Unaudited Quarterly Results (Unaudited)	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Quarterly Financial Information [Text Block]	1 5 . Unaudited Quarterly Results (unaudited) Summarized quarterly financial data during 2017 2016 2017 Quarter Ended March 31 June 30 September 30 December 31 Revenues $ 2,347 $ 2,765 $ 2,697 $ 3,889 Net (loss) income $ (16,360 ) $ (16,636 ) $ (15,352 ) $ (2,665 ) Net loss attributable to noncontrolling interests $ - $ - $ - $ - Net (loss) income attributable to Progenics $ (16,360 ) $ (16,636 ) $ (15,352 ) $ (2,665 ) Net (loss) income per share attributable to Progenics - basic $ (0.23 ) $ (0.24 ) $ (0.22 ) $ (0.04 ) Net (loss) income per share attributable to Progenics - diluted $ (0.23 ) $ (0.24 ) $ (0.22 ) $ (0.04 ) 2016 Quarter Ended March 31 June 30 September 30 December 31 Revenues (1) $ 2,450 $ 8,476 $ 53,850 $ 4,653 Net (loss) income $ (12,673 ) $ (5,657 ) $ 36,282 $ (7,219 ) Net loss attributable to noncontrolling interests $ (18 ) $ (19 ) $ (21 ) $ (15 ) Net (loss) income attributable to Progenics $ (12,655 ) $ (5,638 ) $ 36,303 $ (7,204 ) Net (loss) income per share attributable to Progenics - basic $ (0.18 ) $ (0.08 ) $ 0.52 $ (0.10 ) Net (loss) income per share attributable to Progenics - diluted $ (0.18 ) $ (0.08 ) $ 0.52 $ (0.10 ) ( 1 Revenues in the second fourth 2016 $5.0 $2.0 third 2016 $50.0

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts	12 Months Ended
	Dec. 31, 2017
Notes to Financial Statements
Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]	SCHEDULE II – VALUATION AND QUALIFYING ACCOUNT S Allowance for Doubtful Accounts Year ended December 31, Beginning Balance Additions Charged to General and Administrative Expenses Deductions Accounts Written Off During Period Ending Balance (in thousands) 2017 $ - $ - $ - $ - 2016 $ 10 $ - $ (10 ) $ - 2015 $ 10 $ - $ - $ 10

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2017
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The consolidated financial statements have been prepared on the basis of accounting principles generally accepted in the U.S. (“GAAP”). The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, we evaluate our estimates, including but not
Consolidation, Policy [Policy Text Block]	Principles of Consolidation The condensed consolidated financial statements include the accounts of Progenics as well as its wholly-owned subsidiaries. All material intercompany transactions and balances have been eliminated in consolidation. In December 2015, December 8, 2016, of EXINI and, as of that date, EXINI became a wholly-owned subsidiary with 100% December 2016, $368 $15 2017.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation O ur international subsidiaries generally consider their respective local currency to be their functional currency. Assets and liabilities of these international subsidiaries are translated into U.S. dollars at quarter-end exchange rates and revenues and expenses are translated at average exchange rates during the quarter and year-to-date period. Foreign currency translation adjustments for the reported periods are included in accumulated other comprehensive loss (“AOCL”) in our condensed consolidated statements of comprehensive loss, and the cumulative effect is included in the stockholders’ equity section of our condensed consolidated balance sheets. Realized gains and losses denominated in foreign currencies are recorded in operating expenses in our condensed consolidated statements of operations and were not December 31, 2017, 2016, 2015.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results may
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition We recognize revenue from all sources based on the provisions of the U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin (“SAB”) No. 104 104” 605 605, Revenue Recognition 605, 605 If we are involved in a steering or other committee as part of a multiple-deliverable arrangement, we assess whether our involvement constitutes a performance obligation or a right to participate. For those committees that are deemed obligations, we will evaluate our participation along with other obligations in the arrangement and will attribute revenue to our participation through the period of our committee responsibilities. We recognize revenue for payments that are contingent upon performance solely by our collaborator immediately upon the achievement of the defined event if we have no 605 Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue. Amounts not one Royalty revenue is recognized in the period the sales occur, provided the royalty amounts are fixed or determinable, collection of the related receivable is reasonably assured and we have no During the past three D uring 2016, $50.7 $50.0 $0.7 2016, $7.0 $4.0 $3.0 During 2015 , we recognized $1.5 first 2B/3 140.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expenses Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries ; payroll taxes; employee benefits; materials; supplies; maintenance of research equipment; costs related to research collaboration and licensing agreements; the purchase of in-process research and development; the cost of services provided by outside contractors, including services related to our clinical trials; and the full cost of manufacturing drug for use in research, pre-clinical development, and clinical trials. All costs associated with research and development are expensed as incurred. At each period end , we evaluate the accrued expense balance related to these activities based upon information received from the suppliers and estimated progress towards completion of the research or development objectives to ensure that the balance is reasonably stated. Such estimates are subject to change as additional information becomes available.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Patents As a result of research and development efforts conducted by us, we have applied, or are applying, for a number of patents to protect proprietary inventions. All costs associated with patents are expensed as incurred.
Earnings Per Share, Policy [Policy Text Block]	Net (Loss) Income Per Share We prepare earnings per share (“EPS”) data in accordance with ASC 260 260, Earnings Per Share 2017 2015, 2016, not
Comprehensive Income, Policy [Policy Text Block]	Comprehensive (Loss) Income Comprehensive (loss) income represents the change in net assets of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive (loss) income includes net (loss) income adjusted for the changes in foreign currency translation adjustment. The disclosures required by ASC 220 220, Comprehensive Income 2017, 2016, 2015 no Note 10.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk Financial instruments which potentially subject us to concentrations of risk consist principally of cash, cash equivalents, and receivables. We invest our excess cash in money market funds, which are classified as cash and cash equivalents. We have established guidelines that relate to credit quality, diversification and maturity and that limit exposure to any one no
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents We consider all highly liquid investments which have maturities of three December 31, 2017 2016, $87.2 $137.3 two $3.4 $1.6 two
Receivables, Policy [Policy Text Block]	Accounts Receivable We estimate the level of accounts receivable which ultimately will be uncollectable based on a review of specific receivable balances, industry experience and the current economic environment. We reserve for affected accounts receivable an allowance for doubtful accounts. At December 31, 2017, no
Goodwill and Intangible Assets, Policy [Policy Text Block]	In-Process Research and Development , Othe r Identified Intangible Assets and Goodwill The fair values of in-process research and development ( “IPR&D”) and other identified intangible assets acquired in business combinations are capitalized. The Company utilizes the “income method”, which applies a probability weighting that considers the risk of development and commercialization to the estimated future net cash flows that are derived from projected sales revenues and estimated costs or “replacement costs”, whichever is greater. These projections are based on factors such as relevant market size, patent protection, historical pricing of similar products and expected industry trends. The estimated future net cash flows are then discounted to the present value using an appropriate discount rate. This analysis is performed for each IPR&D project and other identified intangible assets independently. IPR&D assets are treated as indefinite-lived intangible assets until completion or abandonment of the projects, at which time the assets are amortized over the remaining useful life or written off, as appropriate. Other identified intangible assets are amortized over the relevant estimated useful life. The IPR&D assets are tested at least annually or when a triggering event occurs that could indicate a potential impairment and any impairment loss is recognized in our consolidated statements of operations. Goodwill represents excess consideration in a business combination over the fair value of identifiable net assets acquired. Goodwill is not may fair value of the reporting unit (the Company has determined that it has only one No December 31, 2017 2016.
Fair Value Measurement, Policy [Policy Text Block]	Fair Value Measurements In accordance with ASC 820 820, Fair Value Measurements and Disclosures three 820 three ● Level 1 . ● Level 2 1 not . ● Level 3 To estimate the fair values of our financial assets and liabilities, we use valuation approaches within a hierarchy that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that observable inputs be used when available. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of us. Unobservable inputs are inputs that reflect our assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. The fair value hierarchy is divided into three The availability of observable inputs can vary among the various types of financial assets and liabilities. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. In certain cases, the inputs used for measuring fair value may Recurring Fair Value Measurements We believe the carrying amounts of our cash equivalents, accounts receivable, other current assets, other assets, accounts payable, and accrued expenses approximated their fair values as of December 31, 2017 2016. The fair value of the contingent consideration liability represents future potential milestone payments related to the Molecular Insight acquisition. The fair value of the contingent consideration liability is categorized as a Level 3 4. Nonrecurring Fair Value Measurements Our non-financial assets, such as intangible assets and property and equipment, are measured and recorded at fair value on the acquisition date, and if indicators of impairment exist, we assess recoverability by measuring the amount of any impairment by comparing the carrying value of the asset to its then-current estimated fair value (for intangible assets) or to market prices for similar assets (for property and equipment). If the carrying value is not No December 31, 2017. O ther current assets are comprised of prepaid expenses, interest, other receivables, and, in the 2016 one 2016 1
Property, Plant and Equipment, Policy [Policy Text Block]	Fixed Assets Leasehold improvements, furniture and fixtures, and equipment are stated at cost. Furniture, fixtures and equipment are depreciated on a straight-line basis over their estimated useful lives. Leasehold improvements are amortized on a straight-line basis over the life of the lease or of the improvement, whichever is shorter. Costs of construction of long-lived assets are capitalized but are not Expenditures for maintenance and repairs which do not Computer equipment (in years) 3 Machinery and equipment (in years) 5 - 7 Furniture and fixtures (in years) 5 Leasehold improvements (in years) Earlier of life of improvement or lease
Lessee, Leases [Policy Text Block]	Deferred L ease L iability and Incentive Our lease agreements include fixed escalations of minimum annual lease paymen ts and we recognize rental expense on a straight-line basis over the lease terms and record the difference between rent expense and current rental payments as deferred lease liability. Deferred lease incentive includes a construction allowance from our landlord which is amortized as a reduction to rental expense on a straight-line basis over the lease term. As of December 31, 2017, 2016, 2017 2016 Other current liabilities: Deferred lease incentive $ 26 $ 26 Other liabilities: Deferred lease liability $ 1,225 $ 876 Deferred lease incentive $ 303 $ 328
Income Tax, Policy [Policy Text Block]	Income Taxes We account for income taxes in accordance with the provisions of ASC 740 (Topic 740, Income Taxes In accordance with ASC 718 (Topic 718, Compensation – Stock Compensation 505 505, Equity No. 2016 09, Compensation – Stock Compensation (Topic 718 2016 09” January 1, 2017, Uncertain tax positions are accounted for in accordance with ASC 740, to take on a tax return. ASC 740 not 740 may may 50% 740. 50% 740 twelve Note 13.
Risk and Uncertainties, Policy [Policy Text Block]	Risks and Uncertainties To date, w e have relied principally on external funding, license agreements with Valeant, Bayer and others, out-licensing and asset sale arrangements, and royalty and product revenue to finance our operations. There can be no third 2017, 2016, 2015, no December 31, 2017 2016
Legal Costs, Policy [Policy Text Block]	Legal Proceedings From time to time, we may egardless of the merits, is inherently uncertain. The assessment of whether a loss is probable or reasonably possible, and whether the loss or a range of loss is estimable, often involves a series of complex judgments about future events. We record accruals for contingencies to the extent that the occurrence of the contingency is probable and the amount of liability is reasonably estimable. If the reasonable estimate of liability is within a range of amounts and some amount within the range appears to be a better estimate than any other, then we record that amount as an accrual. If no not
New Accounting Pronouncements, Policy [Policy Text Block]	Impact of Recently Issued and Adopted Accounting Standards Recently Adopted In March 2016, Financial Accounting Standards Board (the “FASB”) issued ASU 2016 09, Compensation – Stock Compensation (Topic 718 January 1, 2017. December 31, 2017, not Not In January 2017, No. 2017 01 2017 01” Business Combinations (Topic 805 2017 01 December 15, 2017, not In January 2017, No. 2017 04 2017 04” Intangibles - Goodwill and Other (Topic 350 2 2 2017 04 December 15, 2019. January 1, 2017. not In November 2016, No. 2016 18 2016 18” Statement of Cash Flows (Topic 230 2016 18 2016 18 December 15, 2017, not In August 2016, No. 2016 15 2016 15” Statement of Cash Flows (Topic 230 eight 8 1 2 zero 3 4 5 6 7 8 2016 15 2016 15 December 15, 2017 not In February 2016, No. 2016 02, Leases (Topic 842 2016 02” . 2016 02 2016 02 December 15, 2018, In January 2016, No. 2016 01, Recognition and Measurement of Financial Assets and Financial Liabilities 2016 01” 2016 01 2016 01 December 15, 2017. not not In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 2014 09” 1 2 3 4 5 2014 09 December 15, 2017. 2016, We identified four 1 2 3 4 January 1, 2018 $0.1 not

Note 2 - Summary of Significa25

Note 2 - Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Estimated Useful Lives of Fixed Assets [Table Text Block]	Computer equipment (in years) 3 Machinery and equipment (in years) 5 - 7 Furniture and fixtures (in years) 5 Leasehold improvements (in years) Earlier of life of improvement or lease
Deferred Lease [Table Text Block]	2017 2016 Other current liabilities: Deferred lease incentive $ 26 $ 26 Other liabilities: Deferred lease liability $ 1,225 $ 876 Deferred lease incentive $ 303 $ 328

Note 3 - Goodwill and Acquire26

Note 3 - Goodwill and Acquired Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Intangible Assets and Goodwill [Table Text Block]	Other Intangible Goodwill IPR&D Assets Balance at January 1, 2016 $ 13,074 $ 28,700 $ 2,093 Amortization expense - - (212 ) Balance at December 31, 2016 13,074 28,700 1,881 Amortization expense - - (212 ) Balance at December 31, 2017 $ 13,074 $ 28,700 $ 1,669
Components of Finite Lived Intangible Assets [Table Text Block]	Gross Amount Accumulated Amortization Net Carrying Value Finite lived intangible assets $ 2,120 $ 451 $ 1,669 Total $ 2,120 $ 451 $ 1,669

Note 4 - Fair Value Measureme27

Note 4 - Fair Value Measurements (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Fair Value, Assets Measured on Recurring Basis [Table Text Block]	Fair Value Measurements at December 31, 2017 Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Balance at Identical Assets Inputs Inputs December 31, 2017 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 87,231 $ 87,231 $ - $ - Total assets $ 87,231 $ 87,231 $ - $ - Liabilities: Contingent consideration liability $ 16,800 $ - $ - $ 16,800 Total liabilities $ 16,800 $ - $ - $ 16,800 Fair Value Measurements at December 31, 2016 Quoted Prices in Significant Other Significant Active Markets for Observable Unobservable Balance at Identical Assets Inputs Inputs December 31, 2016 (Level 1) (Level 2) (Level 3) Assets: Money market funds $ 137,340 $ 137,340 $ - $ - Total assets $ 137,340 $ 137,340 $ - $ - Liabilities: Contingent consideration liability $ 14,200 $ - $ - $ 14,200 Total liabilities $ 14,200 $ - $ - $ 14,200
Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]	Program Consideration Form of Payment at Progenics' Option AZEDRA $ 8,000 Cash or Progenics common stock 1404 10,000 Cash or Progenics common stock 1095 5,000 Cash or Progenics common stock $ 23,000 Calendar Year Net Sales Level (in millions) Consideration Form of Payment at Progenics' Option $ 30 $ 5,000 Cash or Progenics common stock $ 60 5,000 Cash or Progenics common stock $ 100 10,000 Cash or Progenics common stock $ 250 20,000 Cash or Progenics common stock $ 500 30,000 Cash or Progenics common stock $ 70,000
Fair Value Inputs, Assets and Liabilities, Quantitative Information [Table Text Block]	Fair Value at December 31, Range 2017 Valuation Technique Unobservable Input (Weighted-Average) Contingent Consideration Liability: AZEDRA commercialization $ 5,500 Probability adjusted Probability of success 72% discounted cash flow model Period of expected milestone achievement 2018 Discount rate 10% 1404 commercialization 4,500 Probability adjusted Probability of success 59% discounted cash flow model Period of expected milestone achievement 2020 Discount rate 10% 1095 commercialization 400 Probability adjusted Probability of success 16% discounted cash flow model Period of expected milestone achievement 2025 Discount rate 10% Net sales targets 6,400 Monte-Carlo simulation Probability of success 16% - 72% Discount rate 10% Total $ 16,800 Fair Value at December 31, Range 2016 Valuation Technique Unobservable Input (Weighted-Average) Contingent Consideration Liability: AZEDRA commercialization $ 3,800 Probability adjusted Probability of success 54% discounted cash flow model Period of expected milestone achievement 2018 Discount rate 10% 1404 commercialization 4,700 Probability adjusted Probability of success 59% discounted cash flow model Period of expected milestone achievement 2019 Discount rate 10% 1095 commercialization 400 Probability adjusted Probability of success 16% discounted cash flow model Period of expected milestone achievement 2024 Discount rate 10% Net sales targets 5,300 Monte-Carlo simulation Probability of success 16% - 59% Discount rate 10% Total $ 14,200
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Liability - Contingent Consideration Fair Value Measurements Using Significant Unobservable Inputs (Level 3) 2017 2016 Balance at beginning of period $ 14,200 $ 18,800 Fair value change included in net income (loss) 2,600 (4,600 ) Balance at end of period $ 16,800 $ 14,200 Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period $ 2,600 $ (4,600 )

Note 5 - Accounts Receivable (T

Note 5 - Accounts Receivable (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]	2017 2016 Royalties $ 3,683 $ 2,407 Collaborators 13 2,000 Other 276 457 Accounts receivable, net $ 3,972 $ 4,864

Note 6 - Fixed Assets (Tables)

Note 6 - Fixed Assets (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Property, Plant and Equipment [Table Text Block]	2017 2016 Machinery and equipment $ 2,516 $ 1,493 Leasehold improvements 1,734 1,640 Computer equipment 714 695 Furniture and fixtures 874 877 Construction in progress - 893 Property and equipment, gross 5,838 5,598 Less - accumulated depreciation (1,716 ) (838 ) Property and equipment, net $ 4,122 $ 4,760

Note 7 - Accrued Expenses (Tabl

Note 7 - Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	2017 2016 Accrued clinical trial costs $ 2,570 $ 4,885 Accrued payroll and related costs 2,400 1,957 Accrued consulting and service fee expenses 1,860 1,026 Accrued legal and professional fees 1,022 1,123 Accrued contract manufacturing costs 666 2,048 Loss contingency for litigation - 4,000 Other 1,037 751 Accrued expenses $ 9,555 $ 15,790

Note 8 - Commitments and Cont31

Note 8 - Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Years ending Minimum Annual December 31, Payments 2018 $ 1,877 2019 1,818 2020 1,852 2021 1,886 2022 2,134 Thereafter 18,549 Total $ 28,116
Licensing Service and Supply Agreements [Table Text Block]	Paid from inception/acquisition to December 31, 2017 Future Commitments (1) Terms Amgen Fremont, Inc. (formerly Abgenix) $ 1,350 $ 5,750 Milestones and royalties to use XenoMouse ® Former member of PSMA LLC $ 428 $ 52,188 Annual minimum royalty payments and milestones to use technology related to PSMA. University of Zurich and the Paul Scherrer Institute $ 500 $ 840 Annual maintenance and license fee payments, milestones and royalties in respect of licensed technology related to 1404. University of Western Ontario $ 78 $ 257 Annual minimum royalty, administration and milestone payments in respect of licensed technology related to AZEDRA. Johns Hopkins University Technology $ 150 $ 2,760 Annual minimum royalty payments and milestones to use technology related to PyL. Selexis Commercial License Agreement $ 59 $ 1,792 Milestones and royalties to use Selexis technology related to PSMA Antibodies.

Note 9 - Non-recourse Long-te32

Note 9 - Non-recourse Long-term Debt, Net (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Maturities of Long-term Debt [Table Text Block]	2018 $ 2,686 2019 3,738 2020 4,858 2021 8,156 2022 12,069 Thereafter 19,245 Total payments $ 50,752

Note 10 - Stockholders' Equity

Note 10 - Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]	Foreign Currency Translation AOCL Balance at January 1, 2017 $ (85 ) $ (85 ) Foreign currency translation adjustment 52 52 Balance at December 31, 2017 $ (33 ) $ (33 )

Note 11 - Stock-based Compens34

Note 11 - Stock-based Compensation (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Share-based Compensation, Stock Options, Activity [Table Text Block]	Weighted Weighted Average Number Average Remaining of Shares Exercise Price Contractual Life Outstanding at January 1, 2017 4,887 $ 7.57 5.81 Granted 1,232 $ 10.34 Exercised (80 ) $ 5.89 Cancelled (159 ) $ 8.96 Expired (345 ) $ 22.42 Outstanding at December 31, 2017 5,535 $ 7.25 6.04 Exercisable at December 31, 2017 3,736 $ 6.71 4.77 Vested and expected to vest at December 31, 2017 5,227 $ 7.15 5.87
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	2017 2016 2015 Risk-free interest rate 2.17% 1.53% 2.00% Expected life (in years) 6.76 6.77 6.97 Expected volatility 72% 74% 81% Expected dividend yield -- -- --
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	2017 2016 2015 Research and development expenses $ 1,371 $ 843 $ 1,099 General and administrative expenses 2,771 1,614 1,849 Total stock-based compensation expense $ 4,142 $ 2,457 $ 2,948

Note 13 - Income Taxes (Tables)

Note 13 - Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	2017 2016 2015 Current taxes: United States $ 3 $ 11 $ - Foreign - - - State (16 ) 22 - Total current taxes $ (13 ) $ 33 $ - Deferred taxes: United States $ (8,777 ) $ - $ - Foreign - - - State (2,882 ) 1,811 (133 ) Total deferred taxes $ (11,659 ) $ 1,811 $ (133 ) (Benefit from) provision for income taxes $ (11,672 ) $ 1,844 $ (133 )
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	2017 2016 Deferred tax assets: Depreciation and amortization $ 100 $ 788 Research & Experimental and Orphan Drug tax credit carry-forwards 33,496 27,361 NYS investment tax credit carry-forwards 1,284 933 AMT credit carry-forwards - 221 Net operation loss carry-forwards 177,313 227,171 Capitalized research and development expenditures 3,066 11,915 Stock compensation 5,666 12,343 Other items 1,279 4,513 Total gross deferred tax assets 222,204 285,245 Less valuation allowance (217,382 ) (285,245 ) Deferred tax assets 4,822 - Deferred tax liability (6,397 ) (13,010 ) Net deferred tax liability $ (1,575 ) $ (13,010 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	2017 2016 2015 U.S. Federal statutory rate 34.0 % 34.0 % 34.0 % State income taxes, net of Federal benefit 1.5 % 10.8 % 4.8 % Foreign rate differential (0.6% ) 2.6 % (0.1% ) Research and experimental and Orphan Drug tax credit 9.4 % (63.0% ) 1.7 % Effect of federal and state tax rate changes (6.1% ) (43.0% ) (4.8% ) Tax reform impact 13.9 % - - Permanent differences (4.4% ) 0.1 % (1.4% ) Stock option shortfalls (3.1% ) 22.3 % (6.1% ) Change in valuation allowance (26.0% ) 50.9 % (27.8% ) Effective tax rate 18.6 % 14.7 % 0.3 %
Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	2017 2016 Beginning uncertain tax benefits $ 2,661 $ 2,661 Prior year - increases (decreases) (710 ) - Current year - increases (decreases) - - Settlements - - Expired statuses - - Ending uncertain tax benefits $ 1,951 $ 2,661

Note 14 - Net (Loss) Income P36

Note 14 - Net (Loss) Income Per Share (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	Net (loss) income Weighted-average attributable shares to Progenics outstanding Per share (Numerator) (Denominator) amount 2017 Basic and diluted $ (51,013 ) 70,284 $ (0.73 ) 2016 Basic $ 10,806 70,003 $ 0.15 Dilutive effect of stock options - 152 Diluted $ 10,806 70,155 $ 0.15 2015 Basic and diluted $ (39,112 ) 69,716 $ (0.56 )
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	2017 2016 2015 Stock options 2,395 3,577 6,381 Contingent consideration liability (1) 2,824 1,644 2,827 Total securities excluded 5,219 5,221 9,208

Note 15 - Unaudited Quarterly37

Note 15 - Unaudited Quarterly Results (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Quarterly Financial Information [Table Text Block]	2017 Quarter Ended March 31 June 30 September 30 December 31 Revenues $ 2,347 $ 2,765 $ 2,697 $ 3,889 Net (loss) income $ (16,360 ) $ (16,636 ) $ (15,352 ) $ (2,665 ) Net loss attributable to noncontrolling interests $ - $ - $ - $ - Net (loss) income attributable to Progenics $ (16,360 ) $ (16,636 ) $ (15,352 ) $ (2,665 ) Net (loss) income per share attributable to Progenics - basic $ (0.23 ) $ (0.24 ) $ (0.22 ) $ (0.04 ) Net (loss) income per share attributable to Progenics - diluted $ (0.23 ) $ (0.24 ) $ (0.22 ) $ (0.04 ) 2016 Quarter Ended March 31 June 30 September 30 December 31 Revenues (1) $ 2,450 $ 8,476 $ 53,850 $ 4,653 Net (loss) income $ (12,673 ) $ (5,657 ) $ 36,282 $ (7,219 ) Net loss attributable to noncontrolling interests $ (18 ) $ (19 ) $ (21 ) $ (15 ) Net (loss) income attributable to Progenics $ (12,655 ) $ (5,638 ) $ 36,303 $ (7,204 ) Net (loss) income per share attributable to Progenics - basic $ (0.18 ) $ (0.08 ) $ 0.52 $ (0.10 ) Net (loss) income per share attributable to Progenics - diluted $ (0.18 ) $ (0.08 ) $ 0.52 $ (0.10 )

Schedule II - Valuation and Q38

Schedule II - Valuation and Qualifying Accounts (Tables)	12 Months Ended
	Dec. 31, 2017
Notes Tables
Valuation and Qualifying Accounts Disclosure [Table Text Block]	Year ended December 31, Beginning Balance Additions Charged to General and Administrative Expenses Deductions Accounts Written Off During Period Ending Balance (in thousands) 2017 $ - $ - $ - $ - 2016 $ 10 $ - $ (10 ) $ - 2015 $ 10 $ - $ - $ 10

Note 1 - Organization and Bus39

Note 1 - Organization and Business (Details Textual) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Cash and Cash Equivalents, at Carrying Value	$ 90,642	$ 90,642	$ 138,909	$ 74,103	$ 119,302
Cash and Cash Equivalents, Period Increase (Decrease)		(48,267)	64,806	(45,199)
Proceeds from Issuance of Long-term Debt	$ 5,000		$ 48,650

Note 2 - Summary of Significa40

Note 2 - Summary of Significant Accounting Policies (Details Textual) $ in Thousands	3 Months Ended			12 Months Ended
	Dec. 31, 2016USD ($)	Sep. 30, 2016USD ($)	Jun. 30, 2016USD ($)	Dec. 31, 2017USD ($)	Dec. 31, 2016USD ($)	Dec. 31, 2015USD ($)	Jan. 01, 2018USD ($)
Return of Estimated Interest Payment for Noncontrolling Interest				$ 15	$ (368)	$ (292)
Licenses Revenue				690	59,081	1,955
Allowance for Doubtful Accounts Receivable, Current				$ 0
Number of Reporting Units				1
Goodwill, Impairment Loss				$ 0	0
Other Comprehensive Income (Loss), Tax				0
Impairment of Intangible Assets (Excluding Goodwill)				0
Subsequent Event [Member] | Accounting Standards Update 2014-09 [Member]
Cumulative Effect of New Accounting Principle in Period of Adoption							$ 100
Money Market Funds [Member]
Cash Equivalents, at Carrying Value	$ 137,300			87,200	137,300
Bank Time Deposits [Member]
Cash Equivalents, at Carrying Value	1,600			$ 3,400	1,600
Valeant [Member]
Licenses Revenue		$ 50,000			50,700
Revenue Recognition, Milestone Method, Revenue Recognized					50,000
Licenses Revenue, Upfront Payment					700
Bayer [Member]
Licenses Revenue	2,000		$ 5,000		7,000
Upfront Payment Receivable	4,000				4,000
Accrued Fees and Other Revenue Receivable	$ 3,000				3,000
CytoDyn's Dosing Milestone [Member]
Revenue Recognition, Milestone Method, Revenue Recognized						$ 1,500
EXINI Diagnostics AB [Member]
Return of Estimated Interest Payment for Noncontrolling Interest					$ 368

Note 2 - Summary of Significa41

Note 2 - Summary of Significant Accounting Policies - Estimated Useful Lives of Fixed Assets (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Computer Equipment [Member]
Estimated useful life (Year)	3 years
Machinery and Equipment [Member] | Minimum [Member]
Estimated useful life (Year)	5 years
Machinery and Equipment [Member] | Maximum [Member]
Estimated useful life (Year)	7 years
Furniture and Fixtures [Member]
Estimated useful life (Year)	5 years
Leasehold Improvements [Member]
Estimated useful life (Year)	12 years 292 days	13 years 292 days
Useful life	Earlier of life of improvement or lease

Note 2 - Summary of Significa42

Note 2 - Summary of Significant Accounting Policies - Deferred Lease Liability and Incentive (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred lease incentive	$ 26	$ 26
Deferred lease liability	1,225	876
Deferred lease incentive	$ 303	$ 328

Note 3 - Goodwill and Acquire43

Note 3 - Goodwill and Acquired Intangible Assets (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Finite-Lived Intangible Asset, Useful Life	8 years
Amortization of Intangible Assets	$ 212	$ 212
Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months	212
Finite-Lived Intangible Assets, Amortization Expense, Year Two	212
Finite-Lived Intangible Assets, Amortization Expense, Year Three	212
Finite-Lived Intangible Assets, Amortization Expense, Year Four	212
Finite-Lived Intangible Assets, Amortization Expense, Year Five	$ 212

Note 3 - Goodwill and Acquire44

Note 3 - Goodwill and Acquired Intangible Assets- Summary of Goodwill and Intangible Assets (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Balance, Goodwill	$ 13,074	$ 13,074
Balance, IPR&D	28,700	28,700	$ 28,700
Balance, Finite-lived Intangible Assets	1,881	2,093
Amortization expense, Finite-lived Intangible Assets	(212)	(212)
Balance, Finite-lived Intangible Assets	$ 1,669	$ 1,881

Note 3 - Goodwill and Acquire45

Note 3 - Goodwill and Acquired Intangible Assets - Components of Finite-lived Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Finite lived intangible assets, gross	$ 2,120
Finite lived intangible assets, accumulated amortization	451
Finite lived intangible assets, net	$ 1,669	$ 1,881	$ 2,093

Note 4 - Fair Value Measureme46

Note 4 - Fair Value Measurements (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Business Combination, Contingent Consideration, Liability, Noncurrent	$ 16,800	$ 14,200
Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability	$ 2,600	$ (4,600)	$ 1,600

Note 4 - Fair Value Measureme47

Note 4 - Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Money market funds	$ 87,231	$ 137,340
Total assets	87,231	137,340
Contingent consideration liability	16,800	14,200
Total liabilities	16,800	14,200
Fair Value, Inputs, Level 1 [Member]
Money market funds	87,231	137,340
Total assets	87,231	137,340
Contingent consideration liability
Total liabilities
Fair Value, Inputs, Level 2 [Member]
Money market funds
Total assets
Contingent consideration liability
Total liabilities
Fair Value, Inputs, Level 3 [Member]
Money market funds
Total assets
Contingent consideration liability	16,800	14,200
Total liabilities	$ 16,800	$ 14,200

Note 4 - Fair Value Measureme48

Note 4 - Fair Value Measurements - Contingent Consideration Liabilities (Details) - Molecular Insight Pharmaceuticals, Inc. [Member] $ in Millions	Dec. 31, 2017USD ($)
Milestone Payment upon First Commercial Sale [Member]
Contingent Consideration	$ 23
Milestone Payment upon Achievement of Net Sales Level 1 [Member]
Contingent Consideration	5
Milestone Payment upon Achievement of Net Sales Level 2 [Member]
Contingent Consideration	5
Milestone Payment upon Achievement of Net Sales Level 3 [Member]
Contingent Consideration	10
Milestone Payment upon Achievement of Net Sales Level 4 [Member]
Contingent Consideration	20
Milestone Payment upon Achievement of Net Sales Level 5 [Member]
Contingent Consideration	30
Milestone Payment upon Achievement of All Levels of Net Sales [Member]
Contingent Consideration	70
AZEDRA Program [Member] | Milestone Payment upon First Commercial Sale [Member]
Contingent Consideration	8
The 1404 Program [Member] | Milestone Payment upon First Commercial Sale [Member]
Contingent Consideration	10
The 1095 Program[Member] | Milestone Payment upon First Commercial Sale [Member]
Contingent Consideration	$ 5

Note 4 - Fair Value Measureme49

Note 4 - Fair Value Measurements - Quantitative Information for Fair Value Measurement of Level 3 (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair value	$ 16.8	$ 14.2
AZEDRA commercialization [Member]
Fair value	$ 5.5	$ 3.8
Valuation technique	Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model
Probability of success	72.00%	54.00%
Discount rate	10.00%	10.00%
MIP - 1404 Commercialization [Member]
Fair value	$ 4.5	$ 4.7
Valuation technique	Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model
Probability of success	59.00%	59.00%
Discount rate	10.00%	10.00%
MIP-1095 Commercialization [Member]
Fair value	$ 0.4	$ 0.4
Valuation technique	Probability adjusted discounted cash flow model	Probability adjusted discounted cash flow model
Probability of success	16.00%	16.00%
Discount rate	10.00%	10.00%
Net sales targets [Member]
Fair value	$ 6.4	$ 5.3
Valuation technique	Monte-Carlo simulation	Monte-Carlo simulation
Discount rate	10.00%	10.00%
Net sales targets [Member] | Minimum [Member]
Probability of success	16.00%	16.00%
Net sales targets [Member] | Maximum [Member]
Probability of success	72.00%	59.00%

Note 4 - Fair Value Measureme50

Note 4 - Fair Value Measurements - Summary of Activities in Financial Instruments With Level 3 Inputs (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Balance	$ 14.2	$ 18.8
Fair value change included in net income (loss)	2.6	(4.6)
Balance	16.8	14.2
Changes in unrealized gains or losses for the period included in earnings (or changes in net assets) for liabilities held at the end of the reporting period	$ 2.6	$ (4.6)

Note 5 - Accounts Receivable -

Note 5 - Accounts Receivable - Summary of Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accounts receivable, net	$ 3,972	$ 4,864
Royalties [Member]
Accounts receivable, net	3,683	2,407
Collaborators [Member]
Accounts receivable, net	13	2,000
Other [Member]
Accounts receivable, net	$ 276	$ 457

Note 6 - Fixed Assets (Details

Note 6 - Fixed Assets (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Leasehold Improvements, Net	$ 1.6	$ 1.6
Depreciation	$ 0.9	$ 1.9	$ 0.5
Leasehold Improvements [Member]
Property, Plant and Equipment, Useful Life	12 years 292 days	13 years 292 days

Note 6 - Fixed Assets - Propert

Note 6 - Fixed Assets - Property, Plant and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Property, Plant and Equipment (gross)	$ 5,838	$ 5,598
Less - accumulated depreciation	(1,716)	(838)
Property and equipment, net	4,122	4,760
Machinery and Equipment [Member]
Property, Plant and Equipment (gross)	2,516	1,493
Leasehold Improvements [Member]
Property, Plant and Equipment (gross)	1,734	1,640
Computer Equipment [Member]
Property, Plant and Equipment (gross)	714	695
Furniture and Fixtures [Member]
Property, Plant and Equipment (gross)	874	877
Construction in Progress [Member]
Property, Plant and Equipment (gross)		$ 893

Note 7 - Accrued Expenses - Sum

Note 7 - Accrued Expenses - Summary of Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Accrued clinical trial costs	$ 2,570	$ 4,885
Accrued payroll and related costs	2,400	1,957
Accrued consulting and service fee expenses	1,860	1,026
Accrued legal and professional fees	1,022	1,123
Accrued contract manufacturing costs	666	2,048
Loss contingency for litigation		4,000
Other	1,037	751
Accrued expenses	$ 9,555	$ 15,790

Note 8 - Commitments and Cont55

Note 8 - Commitments and Contingencies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Operating Leases, Rent Expense, Net	$ 1,900	$ 1,200	$ 1,900
Adjustments to Rent Expense Due to Escalation Clause and Lease Incentives	323	210	49
Additional Facility Charges	100	1,100	2,500
License Fees and Supply Costs	343	324	388
Professional Fees	326	$ 164	$ 54
Settled Litigation [Member] | Anti-Retaliation Termination [Member]
Litigation Settlement, Amount Awarded to Other Party	4,000
Pending Termination [Member]
Commitments Paid from Inception	4,900
Significant Contracts Future Commitments	$ 28,500

Note 8 - Commitments and Cont56

Note 8 - Commitments and Contingencies - Minimum Annual Payments Under Operating Lease Agreements (Details) $ in Thousands	Dec. 31, 2017USD ($)
2,018	$ 1,877
2,019	1,818
2,020	1,852
2,021	1,886
2,022	2,134
Thereafter	18,549
Total	$ 28,116

Note 8 - Commitments and Cont57

Note 8 - Commitments and Contingencies - Licensing, Service and Supply Agreements (Details)	Dec. 31, 2017USD ($)
Amgen Fremont, Inc. Formerly Abgenix [Member]
Commitments, paid from inception	$ 1,350
Future Commitments	5,750	[1]
Former Member of PSMA LLC [Member]
Commitments, paid from inception	428
Future Commitments	52,188	[1]
University of Zurich and Paul Scherrer Institute [Member]
Commitments, paid from inception	500
Future Commitments	840	[1]
University of Western Ontario [Member]
Commitments, paid from inception	78
Future Commitments	257	[1]
Johns Hopkins University Technology [Member]
Commitments, paid from inception	150
Future Commitments	2,760	[1]
Selexis Commercial License Agreement [Member]
Commitments, paid from inception	59
Future Commitments	$ 1,792	[1]
[1]	Amounts based on known contractual obligations as specified in the respective license agreements, which are dependent on the achievement or occurrence of future milestones or events and exclude amounts for royalties which are dependent on future sales and are unknown.

Note 9 - Non-recourse Long-te58

Note 9 - Non-recourse Long-term Debt, Net (Details Textual) - USD ($) $ in Thousands	Nov. 04, 2016	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Proceeds from Issuance of Long-term Debt		$ 5,000		$ 48,650
Royalty-backed Loan [Member]
Proceeds from Issuance of Long-term Debt	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	9.50%
Interest Expense, Debt			$ 5,100

Note 9 - Non-recourse Long-te59

Note 9 - Non-recourse Long-term Debt, Net - Future Principal and Interest Payments on Debt (Details) $ in Thousands	Dec. 31, 2017USD ($)
2,022	$ 12,069
Royalty-backed Loan [Member]
2,018	2,686
2,019	3,738
2,020	4,858
2,021	8,156
Thereafter	19,245
Total payments	$ 50,752

Note 10 - Stockholders' Equit60

Note 10 - Stockholders' Equity (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Jan. 31, 2017	Dec. 31, 2017	Dec. 31, 2017	Mar. 31, 2017	Dec. 31, 2016
Common Stock, Shares Authorized		160,000,000	160,000,000		160,000,000
Common Stock, Par or Stated Value Per Share		$ 0.0013	$ 0.0013		$ 0.0013
Preferred Stock, Shares Authorized		20,000,000	20,000,000		20,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001		$ 0.001
Replacement Shelf Registration				$ 250,000
Common Stock Sales Agreement with Agent, Maximum Aggregate Offering Price	$ 75,000
Stock Issued During Period, Shares, New Issues		854,606
Stock Issued During Period, Value, New Issues		$ 5,000	$ 5,026
Sale of Stock, Price Per Share		$ 6.06	$ 6.06
Common Stock, Shares Subscribed but Unissued		320,182	320,182
Common Stock, Share Subscribed but Unissued, Subscriptions Receivable		$ 2,109	$ 2,109
Sale of Subscribed Common Stock, Price Per Share		$ 6.79	$ 6.79
Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax			$ 0

Note 10 - Stockholders' Equit61

Note 10 - Stockholders' Equity - Components of Accumulated Other Comprehensive Loss (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2017USD ($)
Balance	$ 104,762
Balance	63,453
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(85)
Foreign currency translation adjustment	52
Balance	(33)
AOCI Attributable to Parent [Member]
Balance	(85)
Foreign currency translation adjustment	52
Balance	$ (33)

Note 11 - Stock-based Compens62

Note 11 - Stock-based Compensation (Details Textual) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value	$ 6.96	$ 3.24	$ 5.02
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value	$ 2,700
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value	2,000
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding	2,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value	$ 233	$ 476	$ 465
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%	0.00%
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options	$ 5,500
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	2 years 109 days
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period	10 years
Employee Stock Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	3 years
Employee Stock Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	5 years
The 1996 Amended Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	5,000,000
The 2005 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	11,450,000

Note 11 - Stock-based Compens63

Note 11 - Stock-based Compensation - Summary of Option Activity Under the Plans (Details) - $ / shares shares in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Outstanding, shares (in shares)	4,887
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 7.57
Outstanding, Weighted Average Remaining Contractual Life (Year)	6 years 14 days	5 years 295 days
Granted, shares (in shares)	1,232
Granted, Weighted Average Exercise Price (in dollars per share)	$ 10.34
Exercised, shares (in shares)	(80)
Exercised, Weighted Average Exercise Price (in dollars per share)	$ 5.89
Cancelled, shares (in shares)	(159)
Cancelled, Weighted Average Exercise Price (in dollars per share)	$ 8.96
Expired, shares (in shares)	(345)
Expired, Weighted Average Exercise Price (in dollars per share)	$ 22.42
Outstanding, shares (in shares)	5,535	4,887
Outstanding, Weighted Average Exercise Price (in dollars per share)	$ 7.25	$ 7.57
Exercisable, shares (in shares)	3,736
Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 6.71
Exercisable, Weighted Average Remaining Contractual Life (Year)	4 years 281 days
Vested and expected to vest, shares (in shares)	5,227
Vested and expected to vest, Weighted Average Exercise Price (in dollars per share)	$ 7.15
Vested and expected to vest, Weighted Average Remaining Contractual Life (Year)	5 years 317 days

Note 11 - Stock-based Compens64

Note 11 - Stock-based Compensation - Assumptions Used in Computing the Fair Value of Option Grants (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Risk-free interest rate	2.17%	1.53%	2.00%
Expected life (in years) (Year)	6 years 277 days	6 years 281 days	6 years 354 days
Expected volatility	72.00%	74.00%	81.00%
Expected dividend yield	0.00%	0.00%	0.00%

Note 11 - Stock-based Compens65

Note 11 - Stock-based Compensation - Allocation of Recognized Period Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Total compensation expense recognized	$ 4,142	$ 2,457	$ 2,948
Research and Development Expense [Member]
Total compensation expense recognized	1,371	843	1,099
General and Administrative Expense [Member]
Total compensation expense recognized	$ 2,771	$ 1,614	$ 1,849

Note 12 - Employee Savings Pl66

Note 12 - Employee Savings Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	50.00%
Defined Contribution Plan, Minimum Annual Contribution Per Employee, Percent	1.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	10.00%
Defined Contribution Plan, Cost	$ 302	$ 281	$ 327
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 0	$ 0	$ 0

Note 13 - Income Taxes (Details

Note 13 - Income Taxes (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent		35.00%	34.00%	34.00%
Income Tax Expense (Benefit)		$ (11,672)	$ 1,844	$ (133)
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability		(6,600)
Income Tax Expense (Benefit), Use of Naked Credit as a Source of Income to Release a Portion of Valuation Allowance		(4,800)
Income Tax Expense (Benefit), Refundable AMT Credit		$ (200)
Effective Income Tax Rate Reconciliation, Percent		18.60%	14.70%	0.30%
Deferred Tax Liabilities, Net		$ 1,575	$ 13,010
Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued		0	0	$ 0
Tax Credit Carryforward, Amount		34,200
Liability for Uncertainty in Income Taxes		0	$ 0
Domestic Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability		(3,700)
Operating Loss Carryforwards		664,800
State and Local Jurisdiction [Member]
Operating Loss Carryforwards		$ 569,000
Scenario, Forecast [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent	21.00%

Note 13 - Income Taxes - Compon

Note 13 - Income Taxes - Components of the Provision for (Benefit From) Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Current taxes:
United States	$ 3	$ 11	$ 0
Foreign	0	0	0
State	(16)	22	0
Total current taxes	(13)	33	0
Deferred taxes:
United States	(8,777)	0	0
Foreign	0	0	0
State	(2,882)	1,811	(133)
Total deferred taxes	(11,659)	1,811	(133)
(Benefit from) provision for income taxes	$ (11,672)	$ 1,844	$ (133)

Note 13 - Income Taxes - Deferr

Note 13 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Dec. 31, 2016
Deferred tax assets:
Depreciation and amortization	$ 100	$ 788
Research & Experimental and Orphan Drug tax credit carry-forwards	33,496	27,361
NYS investment tax credit carry-forwards	1,284	933
AMT credit carry-forwards		221
Net operation loss carry-forwards	177,313	227,171
Capitalized research and development expenditures	3,066	11,915
Stock compensation	5,666	12,343
Other items	1,279	4,513
Total gross deferred tax assets	222,204	285,245
Less valuation allowance	(217,382)	(285,245)
Deferred tax assets	4,822
Deferred tax liability	(6,397)	(13,010)
Net deferred tax liability	$ (1,575)	$ (13,010)

Note 13 - Income Taxes - Reconc

Note 13 - Income Taxes - Reconciliation of Income Taxes Computed (Details)	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
U.S. Federal statutory rate	35.00%	34.00%	34.00%
State income taxes, net of Federal benefit	1.50%	10.80%	4.80%
Foreign rate differential	(0.60%)	2.60%	(0.10%)
Research and experimental and Orphan Drug tax credit	9.40%	(63.00%)	1.70%
Effect of federal and state tax rate changes	(6.10%)	(43.00%)	(4.80%)
Tax reform impact	13.90%
Permanent differences	(4.40%)	0.10%	(1.40%)
Stock option shortfalls	(3.10%)	22.30%	(6.10%)
Change in valuation allowance	(26.00%)	50.90%	(27.80%)
Effective tax rate	18.60%	14.70%	0.30%

Note 13 - Income Taxes - Unreco

Note 13 - Income Taxes - Unrecognized Tax Benefits (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Beginning uncertain tax benefits	$ 2,661	$ 2,661
Prior year - increases (decreases)	(710)
Current year - increases (decreases)	0	0
Settlements	0	0
Expired statuses	0	0
Ending uncertain tax benefits	$ 1,951	$ 2,661

Note 14 - Net (Loss) Income P72

Note 14 - Net (Loss) Income Per Share - Calculations of Net (Loss) Income Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Net (loss) income attributable to Progenics	$ (2,665)	$ (15,352)	$ (16,636)	$ (16,360)	$ (7,204)	$ 36,303	$ (5,638)	$ (12,655)	$ (51,013)	$ 10,806	$ (39,112)
Basic and diluted, weighted average shares outstanding (in shares)									70,284	70,003	69,716
Basic and diluted, per share amount (in dollars per share)									$ (0.73)		$ (0.56)
Basic, net loss attributable to Progenics										$ 10,806
Basic, weighted average shares outstanding (in shares)										70,003
Net (loss) income per share attributable to Progenics - basic (in dollars per share)	$ (0.04)	$ (0.22)	$ (0.24)	$ (0.23)	$ (0.10)	$ 0.52	$ (0.08)	$ (0.18)	$ (0.73)	$ 0.15	$ (0.56)
Dilutive effect of stock options, weighted average shares outstanding (in shares)										152
Diluted, net loss attributable to Progenics										$ 10,806
Diluted, weighted average shares outstanding (in shares)									70,284	70,155	69,716
Net (loss) income per share attributable to Progenics - diluted (in dollars per share)	$ (0.04)	$ (0.22)	$ (0.24)	$ (0.23)	$ (0.10)	$ 0.52	$ (0.08)	$ (0.18)	$ (0.73)	$ 0.15	$ (0.56)

Note 14 - Net (Loss) Income P73

Note 14 - Net (Loss) Income Per Share - Common Shares Excluded from Calculation of Diluted Net (Loss) Income Per Share (Details) - shares shares in Thousands		12 Months Ended
		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Antidilutive securities (in shares)		5,219	5,221	9,208
Employee Stock Option [Member]
Antidilutive securities (in shares)		2,395	3,577	6,381
Contingent Consideration Liability [Member]
Antidilutive securities (in shares)	[1]	2,824	1,644	2,827
[1]	Calculated as follows: (a) the contingent consideration liability balance at December 31 divided by (b) the closing stock price of our common stock on the last day of trading of the fiscal year.

Note 15 - Unaudited Quarterly74

Note 15 - Unaudited Quarterly Results (Unaudited) (Details Textual) - USD ($) $ in Thousands	3 Months Ended			12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Licenses Revenue				$ 690	$ 59,081	$ 1,955
Bayer [Member]
Licenses Revenue	$ 2,000		$ 5,000		7,000
Valeant [Member]
Licenses Revenue		$ 50,000			$ 50,700

Note 15 - Unaudited Quarterly75

Note 15 - Unaudited Quarterly Results (Unaudited) - Summarized Quarterly Financial Data (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended												12 Months Ended
	Dec. 31, 2017	Sep. 30, 2017	Jun. 30, 2017	Mar. 31, 2017	Dec. 31, 2016		Sep. 30, 2016		Jun. 30, 2016		Mar. 31, 2016		Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Revenues	$ 3,889	$ 2,697	$ 2,765	$ 2,347	$ 4,653	[1]	$ 53,850	[1]	$ 8,476	[1]	$ 2,450	[1]	$ 11,698	$ 69,429	$ 8,676
Net (loss) income	(2,665)	(15,352)	(16,636)	(16,360)	(7,219)		36,282		(5,657)		(12,673)		(51,013)	10,733	(39,119)
Net loss attributable to noncontrolling interests					(15)		(21)		(19)		(18)			(73)	(7)
Net (loss) income attributable to Progenics	$ (2,665)	$ (15,352)	$ (16,636)	$ (16,360)	$ (7,204)		$ 36,303		$ (5,638)		$ (12,655)		$ (51,013)	$ 10,806	$ (39,112)
Net (loss) income per share attributable to Progenics - basic (in dollars per share)	$ (0.04)	$ (0.22)	$ (0.24)	$ (0.23)	$ (0.10)		$ 0.52		$ (0.08)		$ (0.18)		$ (0.73)	$ 0.15	$ (0.56)
Net (loss) income per share attributable to Progenics - diluted (in dollars per share)	$ (0.04)	$ (0.22)	$ (0.24)	$ (0.23)	$ (0.10)		$ 0.52		$ (0.08)		$ (0.18)		$ (0.73)	$ 0.15	$ (0.56)
[1]	Revenues in the second and fourth quarters of 2016 included $5.0 million and $2.0 million upfront and milestone payments received from Bayer, respectively, and revenues in the third quarter of 2016 included $50.0 million milestone payment received from Valeant.

Schedule II - Valuation and Q76

Schedule II - Valuation and Qualifying Accounts - Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Beginning Balance		$ 10	$ 10
Additions Charged to General and Administrative Expenses	0	0
Deductions Accounts Written Off During Period		(10)	0
Ending Balance	$ 0		$ 10